nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—AKR1B1—uterine cancer	0.625	1	CbGaD
Sulindac—CYP1A1—Progesterone—uterine cancer	0.0515	0.381	CbGbCtD
Sulindac—PTGS2—Etoposide—uterine cancer	0.0273	0.202	CbGbCtD
Sulindac—PTGS1—Etoposide—uterine cancer	0.023	0.171	CbGbCtD
Sulindac—CYP1A2—Progesterone—uterine cancer	0.023	0.17	CbGbCtD
Sulindac—CYP1A2—Etoposide—uterine cancer	0.0103	0.0762	CbGbCtD
Sulindac—MAPK3—artery—uterine cancer	0.00311	0.0534	CbGeAlD
Sulindac—MAPK3—exocrine gland—uterine cancer	0.00271	0.0465	CbGeAlD
Sulindac—PTGDR2—female reproductive system—uterine cancer	0.00228	0.039	CbGeAlD
Sulindac—AKR1B1—myometrium—uterine cancer	0.00207	0.0356	CbGeAlD
Sulindac—AKR1B1—epithelium—uterine cancer	0.00163	0.0279	CbGeAlD
Sulindac—AKR1B1—uterine cervix—uterine cancer	0.00161	0.0277	CbGeAlD
Sulindac—AKR1B1—smooth muscle tissue—uterine cancer	0.00157	0.0269	CbGeAlD
Sulindac—AKR1B1—decidua—uterine cancer	0.00154	0.0264	CbGeAlD
Sulindac—AKR1B1—renal system—uterine cancer	0.00151	0.0259	CbGeAlD
Sulindac—MAPK3—myometrium—uterine cancer	0.0015	0.0258	CbGeAlD
Sulindac—AKR1B1—endometrium—uterine cancer	0.00146	0.025	CbGeAlD
Sulindac—AKR1B1—mammalian vulva—uterine cancer	0.00141	0.0242	CbGeAlD
Sulindac—AKR1B1—uterus—uterine cancer	0.00135	0.0231	CbGeAlD
Sulindac—PTGS1—oviduct—uterine cancer	0.00128	0.0219	CbGeAlD
Sulindac—PPARD—uterine cervix—uterine cancer	0.00127	0.0218	CbGeAlD
Sulindac—AKR1B1—female reproductive system—uterine cancer	0.00121	0.0207	CbGeAlD
Sulindac—PPARD—decidua—uterine cancer	0.00121	0.0207	CbGeAlD
Sulindac—MAPK3—epithelium—uterine cancer	0.00118	0.0202	CbGeAlD
Sulindac—MAPK3—uterine cervix—uterine cancer	0.00117	0.0201	CbGeAlD
Sulindac—MAPK3—smooth muscle tissue—uterine cancer	0.00114	0.0195	CbGeAlD
Sulindac—MAPK3—decidua—uterine cancer	0.00111	0.0191	CbGeAlD
Sulindac—PPARD—mammalian vulva—uterine cancer	0.00111	0.019	CbGeAlD
Sulindac—AKR1B1—female gonad—uterine cancer	0.0011	0.0189	CbGeAlD
Sulindac—MAPK3—renal system—uterine cancer	0.00109	0.0188	CbGeAlD
Sulindac—AKR1B1—vagina—uterine cancer	0.00109	0.0188	CbGeAlD
Sulindac—MAPK3—endometrium—uterine cancer	0.00106	0.0181	CbGeAlD
Sulindac—MAPK3—mammalian vulva—uterine cancer	0.00102	0.0176	CbGeAlD
Sulindac—MAPK3—uterus—uterine cancer	0.000975	0.0167	CbGeAlD
Sulindac—PPARD—female reproductive system—uterine cancer	0.000951	0.0163	CbGeAlD
Sulindac—MAPK3—female reproductive system—uterine cancer	0.000876	0.015	CbGeAlD
Sulindac—PPARD—female gonad—uterine cancer	0.000865	0.0148	CbGeAlD
Sulindac—PPARD—vagina—uterine cancer	0.00086	0.0147	CbGeAlD
Sulindac—PTGS1—artery—uterine cancer	0.000846	0.0145	CbGeAlD
Sulindac—PTGS2—artery—uterine cancer	0.000808	0.0139	CbGeAlD
Sulindac—MAPK3—female gonad—uterine cancer	0.000798	0.0137	CbGeAlD
Sulindac—MAPK3—vagina—uterine cancer	0.000793	0.0136	CbGeAlD
Sulindac—AKR1B1—lymph node—uterine cancer	0.000707	0.0121	CbGeAlD
Sulindac—PPARD—lymph node—uterine cancer	0.000556	0.00954	CbGeAlD
Sulindac—MAPK3—lymph node—uterine cancer	0.000513	0.00879	CbGeAlD
Sulindac—PTGS2—myometrium—uterine cancer	0.00039	0.0067	CbGeAlD
Sulindac—CYP1A1—epithelium—uterine cancer	0.000365	0.00626	CbGeAlD
Sulindac—CYP1A1—uterine cervix—uterine cancer	0.000362	0.00621	CbGeAlD
Sulindac—CYP1A2—renal system—uterine cancer	0.000343	0.00589	CbGeAlD
Sulindac—CYP1A1—renal system—uterine cancer	0.000339	0.00581	CbGeAlD
Sulindac—PTGS1—epithelium—uterine cancer	0.000321	0.0055	CbGeAlD
Sulindac—PTGS1—uterine cervix—uterine cancer	0.000318	0.00545	CbGeAlD
Sulindac—CYP1A1—mammalian vulva—uterine cancer	0.000317	0.00543	CbGeAlD
Sulindac—PTGS1—smooth muscle tissue—uterine cancer	0.000309	0.0053	CbGeAlD
Sulindac—PTGS2—epithelium—uterine cancer	0.000306	0.00526	CbGeAlD
Sulindac—PTGS2—uterine cervix—uterine cancer	0.000304	0.00521	CbGeAlD
Sulindac—CYP1A1—uterus—uterine cancer	0.000302	0.00517	CbGeAlD
Sulindac—PTGS1—renal system—uterine cancer	0.000297	0.0051	CbGeAlD
Sulindac—PTGS2—smooth muscle tissue—uterine cancer	0.000295	0.00507	CbGeAlD
Sulindac—PTGS1—endometrium—uterine cancer	0.000288	0.00493	CbGeAlD
Sulindac—PTGS2—renal system—uterine cancer	0.000284	0.00488	CbGeAlD
Sulindac—PTGS1—mammalian vulva—uterine cancer	0.000278	0.00477	CbGeAlD
Sulindac—PTGS2—endometrium—uterine cancer	0.000275	0.00471	CbGeAlD
Sulindac—CYP1A1—female reproductive system—uterine cancer	0.000271	0.00465	CbGeAlD
Sulindac—PTGS1—uterus—uterine cancer	0.000265	0.00454	CbGeAlD
Sulindac—PTGS2—uterus—uterine cancer	0.000253	0.00434	CbGeAlD
Sulindac—CYP1A1—female gonad—uterine cancer	0.000247	0.00423	CbGeAlD
Sulindac—CYP1A1—vagina—uterine cancer	0.000245	0.00421	CbGeAlD
Sulindac—ALB—lymph node—uterine cancer	0.000244	0.00419	CbGeAlD
Sulindac—PTGS1—female reproductive system—uterine cancer	0.000238	0.00409	CbGeAlD
Sulindac—PTGS2—female reproductive system—uterine cancer	0.000228	0.00391	CbGeAlD
Sulindac—PTGS1—female gonad—uterine cancer	0.000217	0.00372	CbGeAlD
Sulindac—PTGS1—vagina—uterine cancer	0.000215	0.00369	CbGeAlD
Sulindac—PTGS2—female gonad—uterine cancer	0.000207	0.00355	CbGeAlD
Sulindac—PTGS2—vagina—uterine cancer	0.000206	0.00353	CbGeAlD
Sulindac—CYP1A1—lymph node—uterine cancer	0.000159	0.00272	CbGeAlD
Sulindac—Oedema—Dactinomycin—uterine cancer	0.000154	0.00183	CcSEcCtD
Sulindac—Aplastic anaemia—Doxorubicin—uterine cancer	0.000152	0.00181	CcSEcCtD
Sulindac—Thrombocytopenia—Dactinomycin—uterine cancer	0.000151	0.0018	CcSEcCtD
Sulindac—Diarrhoea—Progesterone—uterine cancer	0.000149	0.00178	CcSEcCtD
Sulindac—Erythema multiforme—Etoposide—uterine cancer	0.000148	0.00177	CcSEcCtD
Sulindac—Coma—Doxorubicin—uterine cancer	0.000148	0.00176	CcSEcCtD
Sulindac—Anorexia—Dactinomycin—uterine cancer	0.000147	0.00175	CcSEcCtD
Sulindac—Ecchymosis—Doxorubicin—uterine cancer	0.000147	0.00175	CcSEcCtD
Sulindac—Flushing—Etoposide—uterine cancer	0.000146	0.00173	CcSEcCtD
Sulindac—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000146	0.00173	CcSEcCtD
Sulindac—Photosensitivity—Epirubicin—uterine cancer	0.000145	0.00172	CcSEcCtD
Sulindac—Dizziness—Progesterone—uterine cancer	0.000144	0.00172	CcSEcCtD
Sulindac—Vascular purpura—Epirubicin—uterine cancer	0.000142	0.00169	CcSEcCtD
Sulindac—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000142	0.00169	CcSEcCtD
Sulindac—Hepatic failure—Epirubicin—uterine cancer	0.000141	0.00169	CcSEcCtD
Sulindac—Chills—Etoposide—uterine cancer	0.000141	0.00168	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00014	0.00167	CcSEcCtD
Sulindac—Cardiac failure congestive—Epirubicin—uterine cancer	0.00014	0.00167	CcSEcCtD
Sulindac—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00014	0.00166	CcSEcCtD
Sulindac—PTGS1—lymph node—uterine cancer	0.000139	0.00239	CbGeAlD
Sulindac—Alopecia—Etoposide—uterine cancer	0.000139	0.00165	CcSEcCtD
Sulindac—Vomiting—Progesterone—uterine cancer	0.000139	0.00165	CcSEcCtD
Sulindac—Rash—Progesterone—uterine cancer	0.000137	0.00164	CcSEcCtD
Sulindac—Dermatitis—Progesterone—uterine cancer	0.000137	0.00164	CcSEcCtD
Sulindac—Headache—Progesterone—uterine cancer	0.000137	0.00163	CcSEcCtD
Sulindac—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000135	0.00161	CcSEcCtD
Sulindac—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000135	0.0016	CcSEcCtD
Sulindac—Photosensitivity—Doxorubicin—uterine cancer	0.000134	0.0016	CcSEcCtD
Sulindac—Decreased appetite—Dactinomycin—uterine cancer	0.000134	0.00159	CcSEcCtD
Sulindac—Dysgeusia—Etoposide—uterine cancer	0.000134	0.00159	CcSEcCtD
Sulindac—Renal impairment—Epirubicin—uterine cancer	0.000134	0.00159	CcSEcCtD
Sulindac—PTGS2—lymph node—uterine cancer	0.000133	0.00228	CbGeAlD
Sulindac—Fatigue—Dactinomycin—uterine cancer	0.000133	0.00158	CcSEcCtD
Sulindac—Purpura—Epirubicin—uterine cancer	0.000132	0.00157	CcSEcCtD
Sulindac—Vascular purpura—Doxorubicin—uterine cancer	0.000132	0.00157	CcSEcCtD
Sulindac—Hepatic failure—Doxorubicin—uterine cancer	0.000131	0.00156	CcSEcCtD
Sulindac—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000131	0.00156	CcSEcCtD
Sulindac—Cardiac failure congestive—Doxorubicin—uterine cancer	0.00013	0.00155	CcSEcCtD
Sulindac—Nausea—Progesterone—uterine cancer	0.000129	0.00154	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000127	0.00151	CcSEcCtD
Sulindac—Feeling abnormal—Dactinomycin—uterine cancer	0.000127	0.00151	CcSEcCtD
Sulindac—Ill-defined disorder—Etoposide—uterine cancer	0.000127	0.00151	CcSEcCtD
Sulindac—Anaemia—Etoposide—uterine cancer	0.000126	0.0015	CcSEcCtD
Sulindac—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000126	0.0015	CcSEcCtD
Sulindac—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000126	0.0015	CcSEcCtD
Sulindac—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000125	0.00149	CcSEcCtD
Sulindac—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000125	0.00148	CcSEcCtD
Sulindac—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000124	0.00148	CcSEcCtD
Sulindac—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000124	0.00147	CcSEcCtD
Sulindac—Renal impairment—Doxorubicin—uterine cancer	0.000124	0.00147	CcSEcCtD
Sulindac—Malaise—Etoposide—uterine cancer	0.000123	0.00147	CcSEcCtD
Sulindac—Vertigo—Etoposide—uterine cancer	0.000123	0.00146	CcSEcCtD
Sulindac—Leukopenia—Etoposide—uterine cancer	0.000122	0.00146	CcSEcCtD
Sulindac—Purpura—Doxorubicin—uterine cancer	0.000122	0.00145	CcSEcCtD
Sulindac—Body temperature increased—Dactinomycin—uterine cancer	0.000122	0.00145	CcSEcCtD
Sulindac—Loss of consciousness—Etoposide—uterine cancer	0.00012	0.00143	CcSEcCtD
Sulindac—Convulsion—Etoposide—uterine cancer	0.000118	0.00141	CcSEcCtD
Sulindac—Hypertension—Etoposide—uterine cancer	0.000118	0.0014	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000118	0.0014	CcSEcCtD
Sulindac—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000117	0.0014	CcSEcCtD
Sulindac—Chest pain—Etoposide—uterine cancer	0.000116	0.00139	CcSEcCtD
Sulindac—Discomfort—Etoposide—uterine cancer	0.000115	0.00137	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000115	0.00136	CcSEcCtD
Sulindac—Hypersensitivity—Dactinomycin—uterine cancer	0.000113	0.00135	CcSEcCtD
Sulindac—Gastritis—Epirubicin—uterine cancer	0.000113	0.00134	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—uterine cancer	0.000112	0.00134	CcSEcCtD
Sulindac—Anaphylactic shock—Etoposide—uterine cancer	0.000111	0.00133	CcSEcCtD
Sulindac—Asthenia—Dactinomycin—uterine cancer	0.000111	0.00132	CcSEcCtD
Sulindac—Thrombocytopenia—Etoposide—uterine cancer	0.000109	0.0013	CcSEcCtD
Sulindac—Tachycardia—Etoposide—uterine cancer	0.000109	0.0013	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—uterine cancer	0.000109	0.0013	CcSEcCtD
Sulindac—Hyperhidrosis—Etoposide—uterine cancer	0.000108	0.00128	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—uterine cancer	0.000108	0.00128	CcSEcCtD
Sulindac—Anorexia—Etoposide—uterine cancer	0.000106	0.00127	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000106	0.00126	CcSEcCtD
Sulindac—Diarrhoea—Dactinomycin—uterine cancer	0.000105	0.00126	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—uterine cancer	0.000104	0.00124	CcSEcCtD
Sulindac—Hypotension—Etoposide—uterine cancer	0.000104	0.00124	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—uterine cancer	0.000104	0.00124	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—uterine cancer	0.000104	0.00124	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—uterine cancer	0.000103	0.00122	CcSEcCtD
Sulindac—Dysuria—Epirubicin—uterine cancer	0.000103	0.00122	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—uterine cancer	0.000101	0.0012	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—uterine cancer	0.0001	0.00119	CcSEcCtD
Sulindac—Paraesthesia—Etoposide—uterine cancer	0.0001	0.00119	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—uterine cancer	9.97e-05	0.00119	CcSEcCtD
Sulindac—Dyspnoea—Etoposide—uterine cancer	9.94e-05	0.00118	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—uterine cancer	9.91e-05	0.00118	CcSEcCtD
Sulindac—Somnolence—Etoposide—uterine cancer	9.91e-05	0.00118	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—uterine cancer	9.86e-05	0.00117	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—uterine cancer	9.79e-05	0.00117	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—uterine cancer	9.72e-05	0.00116	CcSEcCtD
Sulindac—Rash—Dactinomycin—uterine cancer	9.71e-05	0.00116	CcSEcCtD
Sulindac—Decreased appetite—Etoposide—uterine cancer	9.69e-05	0.00115	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—uterine cancer	9.66e-05	0.00115	CcSEcCtD
Sulindac—Renal failure—Epirubicin—uterine cancer	9.63e-05	0.00115	CcSEcCtD
Sulindac—Fatigue—Etoposide—uterine cancer	9.61e-05	0.00114	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—uterine cancer	9.61e-05	0.00114	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—uterine cancer	9.55e-05	0.00114	CcSEcCtD
Sulindac—Jaundice—Epirubicin—uterine cancer	9.55e-05	0.00114	CcSEcCtD
Sulindac—Constipation—Etoposide—uterine cancer	9.53e-05	0.00114	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—uterine cancer	9.53e-05	0.00113	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—uterine cancer	9.51e-05	0.00113	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—uterine cancer	9.51e-05	0.00113	CcSEcCtD
Sulindac—Sweating—Epirubicin—uterine cancer	9.39e-05	0.00112	CcSEcCtD
Sulindac—Haematuria—Epirubicin—uterine cancer	9.34e-05	0.00111	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—uterine cancer	9.28e-05	0.00111	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—uterine cancer	9.24e-05	0.0011	CcSEcCtD
Sulindac—Feeling abnormal—Etoposide—uterine cancer	9.19e-05	0.00109	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—uterine cancer	9.17e-05	0.00109	CcSEcCtD
Sulindac—Nausea—Dactinomycin—uterine cancer	9.15e-05	0.00109	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—uterine cancer	9.14e-05	0.00109	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—uterine cancer	9.12e-05	0.00109	CcSEcCtD
Sulindac—Gastrointestinal pain—Etoposide—uterine cancer	9.12e-05	0.00109	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	8.99e-05	0.00107	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—uterine cancer	8.91e-05	0.00106	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—uterine cancer	8.89e-05	0.00106	CcSEcCtD
Sulindac—Urticaria—Etoposide—uterine cancer	8.86e-05	0.00105	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—uterine cancer	8.84e-05	0.00105	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—uterine cancer	8.84e-05	0.00105	CcSEcCtD
Sulindac—Body temperature increased—Etoposide—uterine cancer	8.81e-05	0.00105	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—uterine cancer	8.81e-05	0.00105	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—uterine cancer	8.8e-05	0.00105	CcSEcCtD
Sulindac—Sweating—Doxorubicin—uterine cancer	8.69e-05	0.00104	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—uterine cancer	8.65e-05	0.00103	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—uterine cancer	8.55e-05	0.00102	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—uterine cancer	8.48e-05	0.00101	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—uterine cancer	8.46e-05	0.00101	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—uterine cancer	8.32e-05	0.000991	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—uterine cancer	8.21e-05	0.000978	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—uterine cancer	8.2e-05	0.000977	CcSEcCtD
Sulindac—Flushing—Epirubicin—uterine cancer	8.16e-05	0.000972	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—uterine cancer	8.14e-05	0.000969	CcSEcCtD
Sulindac—Asthenia—Etoposide—uterine cancer	8e-05	0.000953	CcSEcCtD
Sulindac—Chills—Epirubicin—uterine cancer	7.89e-05	0.00094	CcSEcCtD
Sulindac—Pruritus—Etoposide—uterine cancer	7.89e-05	0.000939	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—uterine cancer	7.86e-05	0.000936	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—uterine cancer	7.84e-05	0.000934	CcSEcCtD
Sulindac—Alopecia—Epirubicin—uterine cancer	7.77e-05	0.000926	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—uterine cancer	7.7e-05	0.000917	CcSEcCtD
Sulindac—Diarrhoea—Etoposide—uterine cancer	7.63e-05	0.000909	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—uterine cancer	7.59e-05	0.000904	CcSEcCtD
Sulindac—Flushing—Doxorubicin—uterine cancer	7.55e-05	0.0009	CcSEcCtD
Sulindac—Flatulence—Epirubicin—uterine cancer	7.55e-05	0.000899	CcSEcCtD
Sulindac—Tension—Epirubicin—uterine cancer	7.51e-05	0.000895	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—uterine cancer	7.5e-05	0.000893	CcSEcCtD
Sulindac—Nervousness—Epirubicin—uterine cancer	7.44e-05	0.000886	CcSEcCtD
Sulindac—Dizziness—Etoposide—uterine cancer	7.37e-05	0.000878	CcSEcCtD
Sulindac—Chills—Doxorubicin—uterine cancer	7.3e-05	0.00087	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—uterine cancer	7.27e-05	0.000866	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—uterine cancer	7.22e-05	0.00086	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—uterine cancer	7.19e-05	0.000857	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—uterine cancer	7.11e-05	0.000846	CcSEcCtD
Sulindac—Vomiting—Etoposide—uterine cancer	7.09e-05	0.000844	CcSEcCtD
Sulindac—Anaemia—Epirubicin—uterine cancer	7.08e-05	0.000843	CcSEcCtD
Sulindac—Rash—Etoposide—uterine cancer	7.03e-05	0.000837	CcSEcCtD
Sulindac—Dermatitis—Etoposide—uterine cancer	7.02e-05	0.000836	CcSEcCtD
Sulindac—Headache—Etoposide—uterine cancer	6.98e-05	0.000832	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—uterine cancer	6.98e-05	0.000832	CcSEcCtD
Sulindac—Tension—Doxorubicin—uterine cancer	6.95e-05	0.000828	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—uterine cancer	6.94e-05	0.000826	CcSEcCtD
Sulindac—Malaise—Epirubicin—uterine cancer	6.91e-05	0.000822	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—uterine cancer	6.88e-05	0.00082	CcSEcCtD
Sulindac—Vertigo—Epirubicin—uterine cancer	6.88e-05	0.000819	CcSEcCtD
Sulindac—Syncope—Epirubicin—uterine cancer	6.87e-05	0.000818	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—uterine cancer	6.85e-05	0.000816	CcSEcCtD
Sulindac—Palpitations—Epirubicin—uterine cancer	6.77e-05	0.000806	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—uterine cancer	6.73e-05	0.000802	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—uterine cancer	6.68e-05	0.000795	CcSEcCtD
Sulindac—Convulsion—Epirubicin—uterine cancer	6.63e-05	0.00079	CcSEcCtD
Sulindac—Nausea—Etoposide—uterine cancer	6.62e-05	0.000789	CcSEcCtD
Sulindac—Hypertension—Epirubicin—uterine cancer	6.61e-05	0.000787	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—uterine cancer	6.57e-05	0.000783	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—uterine cancer	6.55e-05	0.00078	CcSEcCtD
Sulindac—Chest pain—Epirubicin—uterine cancer	6.52e-05	0.000776	CcSEcCtD
Sulindac—Myalgia—Epirubicin—uterine cancer	6.52e-05	0.000776	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—uterine cancer	6.52e-05	0.000776	CcSEcCtD
Sulindac—Discomfort—Epirubicin—uterine cancer	6.44e-05	0.000767	CcSEcCtD
Sulindac—Malaise—Doxorubicin—uterine cancer	6.39e-05	0.000761	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—uterine cancer	6.37e-05	0.000758	CcSEcCtD
Sulindac—Syncope—Doxorubicin—uterine cancer	6.35e-05	0.000757	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—uterine cancer	6.34e-05	0.000755	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—uterine cancer	6.26e-05	0.000746	CcSEcCtD
Sulindac—Oedema—Epirubicin—uterine cancer	6.25e-05	0.000744	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—uterine cancer	6.25e-05	0.000744	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—uterine cancer	6.23e-05	0.000742	CcSEcCtD
Sulindac—Shock—Epirubicin—uterine cancer	6.15e-05	0.000732	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—uterine cancer	6.14e-05	0.000731	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—uterine cancer	6.12e-05	0.000729	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—uterine cancer	6.12e-05	0.000729	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—uterine cancer	6.1e-05	0.000726	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—uterine cancer	6.04e-05	0.00072	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—uterine cancer	6.03e-05	0.000718	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—uterine cancer	6.03e-05	0.000718	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—uterine cancer	6.03e-05	0.000718	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—uterine cancer	5.96e-05	0.00071	CcSEcCtD
Sulindac—Anorexia—Epirubicin—uterine cancer	5.96e-05	0.00071	CcSEcCtD
Sulindac—Hypotension—Epirubicin—uterine cancer	5.84e-05	0.000696	CcSEcCtD
Sulindac—Oedema—Doxorubicin—uterine cancer	5.78e-05	0.000689	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—uterine cancer	5.78e-05	0.000689	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.69e-05	0.000678	CcSEcCtD
Sulindac—Shock—Doxorubicin—uterine cancer	5.69e-05	0.000678	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—uterine cancer	5.66e-05	0.000674	CcSEcCtD
Sulindac—Insomnia—Epirubicin—uterine cancer	5.65e-05	0.000673	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—uterine cancer	5.64e-05	0.000672	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—uterine cancer	5.61e-05	0.000668	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—uterine cancer	5.59e-05	0.000666	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—uterine cancer	5.57e-05	0.000664	CcSEcCtD
Sulindac—Somnolence—Epirubicin—uterine cancer	5.56e-05	0.000662	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—uterine cancer	5.51e-05	0.000656	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—uterine cancer	5.5e-05	0.000655	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—uterine cancer	5.43e-05	0.000647	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—uterine cancer	5.4e-05	0.000644	CcSEcCtD
Sulindac—Fatigue—Epirubicin—uterine cancer	5.39e-05	0.000642	CcSEcCtD
Sulindac—Constipation—Epirubicin—uterine cancer	5.34e-05	0.000637	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.27e-05	0.000627	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—uterine cancer	5.23e-05	0.000623	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—uterine cancer	5.19e-05	0.000618	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—uterine cancer	5.16e-05	0.000614	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—uterine cancer	5.15e-05	0.000613	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—uterine cancer	5.14e-05	0.000612	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—uterine cancer	5.11e-05	0.000609	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—uterine cancer	5.09e-05	0.000606	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—uterine cancer	5.03e-05	0.000599	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—uterine cancer	4.99e-05	0.000594	CcSEcCtD
Sulindac—Urticaria—Epirubicin—uterine cancer	4.96e-05	0.000591	CcSEcCtD
Sulindac—Constipation—Doxorubicin—uterine cancer	4.95e-05	0.000589	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—uterine cancer	4.94e-05	0.000588	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—uterine cancer	4.77e-05	0.000568	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—uterine cancer	4.73e-05	0.000563	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—uterine cancer	4.6e-05	0.000548	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—uterine cancer	4.59e-05	0.000547	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—uterine cancer	4.57e-05	0.000544	CcSEcCtD
Sulindac—Asthenia—Epirubicin—uterine cancer	4.48e-05	0.000534	CcSEcCtD
Sulindac—Pruritus—Epirubicin—uterine cancer	4.42e-05	0.000527	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—uterine cancer	4.28e-05	0.000509	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—uterine cancer	4.26e-05	0.000507	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—uterine cancer	4.15e-05	0.000494	CcSEcCtD
Sulindac—Dizziness—Epirubicin—uterine cancer	4.13e-05	0.000492	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—uterine cancer	4.09e-05	0.000487	CcSEcCtD
Sulindac—Vomiting—Epirubicin—uterine cancer	3.97e-05	0.000473	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—uterine cancer	3.96e-05	0.000471	CcSEcCtD
Sulindac—Rash—Epirubicin—uterine cancer	3.94e-05	0.000469	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—uterine cancer	3.94e-05	0.000469	CcSEcCtD
Sulindac—Headache—Epirubicin—uterine cancer	3.92e-05	0.000466	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—uterine cancer	3.82e-05	0.000455	CcSEcCtD
Sulindac—Nausea—Epirubicin—uterine cancer	3.71e-05	0.000442	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—uterine cancer	3.68e-05	0.000438	CcSEcCtD
Sulindac—Rash—Doxorubicin—uterine cancer	3.65e-05	0.000434	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—uterine cancer	3.64e-05	0.000434	CcSEcCtD
Sulindac—Headache—Doxorubicin—uterine cancer	3.62e-05	0.000431	CcSEcCtD
Sulindac—Nausea—Doxorubicin—uterine cancer	3.43e-05	0.000409	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—CTNNB1—uterine cancer	1.42e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KRAS—uterine cancer	1.42e-05	0.000146	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKR1C1—uterine cancer	1.42e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—ERBB2—uterine cancer	1.4e-05	0.000144	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	1.38e-05	0.000142	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PTEN—uterine cancer	1.38e-05	0.000142	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SOCS3—uterine cancer	1.38e-05	0.000141	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.37e-05	0.000141	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKR1B1—uterine cancer	1.36e-05	0.00014	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—STAR—uterine cancer	1.36e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDKN2A—uterine cancer	1.35e-05	0.000139	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—AKT1—uterine cancer	1.35e-05	0.000138	CbGpPWpGaD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	1.35e-05	0.000138	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.35e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—uterine cancer	1.34e-05	0.000138	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKR1C1—uterine cancer	1.34e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDKN1B—uterine cancer	1.34e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	1.33e-05	0.000136	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EP300—uterine cancer	1.32e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—CDKN2B—uterine cancer	1.31e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.31e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—PIK3CA—uterine cancer	1.3e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—KRAS—uterine cancer	1.28e-05	0.000132	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—RRM2—uterine cancer	1.26e-05	0.00013	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—uterine cancer	1.25e-05	0.000128	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKR1B1—uterine cancer	1.24e-05	0.000127	CbGpPWpGaD
Sulindac—ALB—Metabolism—STAR—uterine cancer	1.24e-05	0.000127	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ERBB2—uterine cancer	1.24e-05	0.000127	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—uterine cancer	1.23e-05	0.000127	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—DCN—uterine cancer	1.23e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—uterine cancer	1.23e-05	0.000126	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.23e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CTNNB1—uterine cancer	1.22e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKR1C3—uterine cancer	1.22e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN2B—uterine cancer	1.22e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—uterine cancer	1.21e-05	0.000124	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—POLD1—uterine cancer	1.2e-05	0.000123	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NDUFB11—uterine cancer	1.2e-05	0.000123	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SRD5A2—uterine cancer	1.2e-05	0.000123	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDKN1B—uterine cancer	1.2e-05	0.000123	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—SMAD3—uterine cancer	1.2e-05	0.000123	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PGR—uterine cancer	1.19e-05	0.000122	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—EP300—uterine cancer	1.18e-05	0.000121	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.17e-05	0.00012	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.17e-05	0.00012	CbGpPWpGaD
Sulindac—PTGS2—Disease—DCN—uterine cancer	1.16e-05	0.000119	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP11A1—uterine cancer	1.16e-05	0.000119	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FGFR2—uterine cancer	1.15e-05	0.000118	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CDKN1B—uterine cancer	1.14e-05	0.000117	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EP300—uterine cancer	1.14e-05	0.000117	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—YWHAE—uterine cancer	1.13e-05	0.000116	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKR1C1—uterine cancer	1.13e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—EP300—uterine cancer	1.12e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Disease—SMAD3—uterine cancer	1.11e-05	0.000114	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.1e-05	0.000113	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKR1C3—uterine cancer	1.09e-05	0.000112	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—uterine cancer	1.09e-05	0.000112	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FBXW7—uterine cancer	1.09e-05	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CTNNB1—uterine cancer	1.08e-05	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—uterine cancer	1.08e-05	0.000111	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.07e-05	0.00011	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—POLD1—uterine cancer	1.07e-05	0.00011	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—AKT1—uterine cancer	1.06e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—uterine cancer	1.06e-05	0.000109	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—uterine cancer	1.06e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Disease—FGFR2—uterine cancer	1.06e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—uterine cancer	1.06e-05	0.000108	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PTEN—uterine cancer	1.05e-05	0.000108	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—EP300—uterine cancer	1.05e-05	0.000108	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—uterine cancer	1.04e-05	0.000107	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.04e-05	0.000106	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKR1C3—uterine cancer	1.03e-05	0.000106	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTHFR—uterine cancer	1.02e-05	0.000104	CbGpPWpGaD
Sulindac—PTGS2—Disease—HMGA1—uterine cancer	1.01e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EP300—uterine cancer	1.01e-05	0.000103	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—RRM2—uterine cancer	1e-05	0.000103	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKR1C1—uterine cancer	9.99e-06	0.000102	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	9.87e-06	0.000101	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PIK3CA—uterine cancer	9.76e-06	0.0001	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—ESR1—uterine cancer	9.75e-06	0.0001	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—DCN—uterine cancer	9.74e-06	9.99e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—POLD1—uterine cancer	9.74e-06	9.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STK11—uterine cancer	9.49e-06	9.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL2—uterine cancer	9.45e-06	9.69e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—uterine cancer	9.44e-06	9.68e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—uterine cancer	9.4e-06	9.64e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTEN—uterine cancer	9.3e-06	9.53e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FBXW7—uterine cancer	9.22e-06	9.46e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP11A1—uterine cancer	9.18e-06	9.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—uterine cancer	9.16e-06	9.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKR1C1—uterine cancer	9.11e-06	9.34e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—uterine cancer	9.03e-06	9.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—uterine cancer	8.99e-06	9.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—RRM2—uterine cancer	8.91e-06	9.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SOCS3—uterine cancer	8.89e-06	9.12e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—EP300—uterine cancer	8.87e-06	9.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.75e-06	8.97e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1B1—uterine cancer	8.68e-06	8.9e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—STAR—uterine cancer	8.68e-06	8.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKR1C3—uterine cancer	8.67e-06	8.89e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—DCN—uterine cancer	8.65e-06	8.87e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	8.58e-06	8.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDH1—uterine cancer	8.53e-06	8.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN2B—uterine cancer	8.51e-06	8.73e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—STK11—uterine cancer	8.51e-06	8.72e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP19A1—uterine cancer	8.51e-06	8.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1R—uterine cancer	8.26e-06	8.48e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PIK3CA—uterine cancer	8.26e-06	8.47e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP11A1—uterine cancer	8.15e-06	8.35e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—RRM2—uterine cancer	8.12e-06	8.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—uterine cancer	8.09e-06	8.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—uterine cancer	7.99e-06	8.19e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.98e-06	8.19e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—uterine cancer	7.97e-06	8.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—DCN—uterine cancer	7.88e-06	8.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—uterine cancer	7.79e-06	7.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SMAD3—uterine cancer	7.77e-06	7.97e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	7.71e-06	7.91e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKR1C3—uterine cancer	7.69e-06	7.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—uterine cancer	7.64e-06	7.84e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.61e-06	7.81e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—uterine cancer	7.54e-06	7.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL8—uterine cancer	7.47e-06	7.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—uterine cancer	7.44e-06	7.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP11A1—uterine cancer	7.43e-06	7.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGFR2—uterine cancer	7.41e-06	7.6e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN2B—uterine cancer	7.23e-06	7.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB2—uterine cancer	7.2e-06	7.38e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKR1C3—uterine cancer	7.01e-06	7.19e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—uterine cancer	6.89e-06	7.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—uterine cancer	6.88e-06	7.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—uterine cancer	6.88e-06	7.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—POLD1—uterine cancer	6.81e-06	6.99e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—STK11—uterine cancer	6.75e-06	6.93e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP19A1—uterine cancer	6.75e-06	6.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—uterine cancer	6.75e-06	6.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1B—uterine cancer	6.67e-06	6.84e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB2—uterine cancer	6.65e-06	6.82e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SMAD3—uterine cancer	6.6e-06	6.77e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—uterine cancer	6.56e-06	6.73e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MTHFR—uterine cancer	6.39e-06	6.56e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1C1—uterine cancer	6.37e-06	6.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ESR1—uterine cancer	6.34e-06	6.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.34e-06	6.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTNNB1—uterine cancer	6.3e-06	6.46e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	6.3e-06	6.46e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGFR2—uterine cancer	6.29e-06	6.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1B—uterine cancer	6.16e-06	6.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—uterine cancer	6.14e-06	6.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—uterine cancer	6.07e-06	6.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTHFR—uterine cancer	6.06e-06	6.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.04e-06	6.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—uterine cancer	5.99e-06	6.15e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—STK11—uterine cancer	5.99e-06	6.15e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP19A1—uterine cancer	5.99e-06	6.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EP300—uterine cancer	5.85e-06	6e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—uterine cancer	5.82e-06	5.96e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—RRM2—uterine cancer	5.68e-06	5.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—uterine cancer	5.67e-06	5.81e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.63e-06	5.78e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.63e-06	5.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL2—uterine cancer	5.58e-06	5.73e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—DCN—uterine cancer	5.51e-06	5.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—uterine cancer	5.48e-06	5.62e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—STK11—uterine cancer	5.46e-06	5.6e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP19A1—uterine cancer	5.46e-06	5.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EP300—uterine cancer	5.41e-06	5.54e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—EP300—uterine cancer	5.37e-06	5.51e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.36e-06	5.5e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—uterine cancer	5.36e-06	5.49e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP11A1—uterine cancer	5.19e-06	5.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—uterine cancer	5.16e-06	5.29e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.13e-06	5.26e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—uterine cancer	5.09e-06	5.22e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—uterine cancer	5.07e-06	5.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—uterine cancer	5.06e-06	5.19e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—uterine cancer	5.03e-06	5.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1C3—uterine cancer	4.9e-06	5.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.89e-06	5.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—uterine cancer	4.74e-06	4.86e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—uterine cancer	4.71e-06	4.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—uterine cancer	4.65e-06	4.77e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—uterine cancer	4.5e-06	4.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.47e-06	4.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—uterine cancer	4.41e-06	4.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—uterine cancer	4.39e-06	4.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—uterine cancer	4.35e-06	4.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—uterine cancer	4.33e-06	4.44e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—uterine cancer	4.33e-06	4.44e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—uterine cancer	4.31e-06	4.42e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—uterine cancer	4.11e-06	4.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—uterine cancer	4.07e-06	4.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—uterine cancer	4.01e-06	4.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—uterine cancer	4e-06	4.1e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—uterine cancer	3.97e-06	4.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—uterine cancer	3.97e-06	4.07e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.97e-06	4.07e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—uterine cancer	3.95e-06	4.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—uterine cancer	3.87e-06	3.97e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—uterine cancer	3.84e-06	3.94e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—STK11—uterine cancer	3.82e-06	3.92e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP19A1—uterine cancer	3.82e-06	3.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EP300—uterine cancer	3.79e-06	3.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—uterine cancer	3.7e-06	3.79e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—uterine cancer	3.68e-06	3.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—uterine cancer	3.66e-06	3.75e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.62e-06	3.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.59e-06	3.68e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—uterine cancer	3.58e-06	3.68e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—uterine cancer	3.56e-06	3.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—uterine cancer	3.54e-06	3.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—uterine cancer	3.54e-06	3.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—uterine cancer	3.52e-06	3.61e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—uterine cancer	3.46e-06	3.55e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.42e-06	3.51e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—EP300—uterine cancer	3.39e-06	3.48e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—uterine cancer	3.37e-06	3.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—uterine cancer	3.27e-06	3.35e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—uterine cancer	3.25e-06	3.33e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EP300—uterine cancer	3.21e-06	3.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—uterine cancer	3.05e-06	3.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—uterine cancer	3.01e-06	3.08e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—uterine cancer	2.87e-06	2.94e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—uterine cancer	2.82e-06	2.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—uterine cancer	2.8e-06	2.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—uterine cancer	2.71e-06	2.78e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—EP300—uterine cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—uterine cancer	2.59e-06	2.66e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—uterine cancer	2.59e-06	2.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.53e-06	2.6e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—uterine cancer	2.51e-06	2.57e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—uterine cancer	2.51e-06	2.57e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—EP300—uterine cancer	2.39e-06	2.45e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—uterine cancer	2.38e-06	2.44e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—uterine cancer	2.29e-06	2.35e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—uterine cancer	2.28e-06	2.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—uterine cancer	2.2e-06	2.26e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—EP300—uterine cancer	2.18e-06	2.23e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—uterine cancer	2.05e-06	2.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—uterine cancer	1.99e-06	2.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—uterine cancer	1.94e-06	1.99e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—uterine cancer	1.77e-06	1.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—uterine cancer	1.63e-06	1.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—uterine cancer	1.61e-06	1.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—uterine cancer	1.6e-06	1.64e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—EP300—uterine cancer	1.52e-06	1.56e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—uterine cancer	1.44e-06	1.48e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—uterine cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—uterine cancer	9.21e-07	9.44e-06	CbGpPWpGaD
